FDA Peptide Review Is a Make-or-Break Catalyst — Upgrade to Long on Hims & Hers
Hims & Hers (HIMS) is trading at an attractive junction: a peptide program under FDA review creates a binary upside while recent partnership wins and improving technical momentum reduce some execution risk. We upgrade to a long rating with a clear entry at $26.41, a $40 target over a 180-trading-day horizon, and an $18 stop — this is a high-risk, h…